Tarsus Pharmaceuticals (TARS)
US Market

Tarsus Pharmaceuticals (TARS) Stock Price & Analysis


TARS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$11.33 - $25.25
Previous Close$17.29
Average Volume (3M)546.42K
Market Cap
Enterprise Value$349.57M
Total Cash (Recent Filing)$246.88M
Total Debt (Recent Filing)$29.71M
Price to Earnings (P/E)-4.5
Mar 11, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.83
Shares Outstanding33,104,612
10 Day Avg. Volume593,715
30 Day Avg. Volume546,425
Standard Deviation0.18
Financial Highlights & Ratios
Price to Book (P/B)2.57
Price to Sales (P/S)21.95
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue24.32
Enterprise Value/Gross Profit14.35
Enterprise Value/Ebitda-4.80
Price Target Upside168.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6



Ownership Overview

9.09% Mutual Funds
69.18% Other Institutional Investors
21.73% Public Companies and
Individual Investors


What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $11.33 and its highest was $25.25 in the past 12 months.
    What is Tarsus Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Tarsus Pharmaceuticals’s upcoming earnings report date?
    Tarsus Pharmaceuticals’s upcoming earnings report date is Mar 11, 2024 which is in 92 days.
      How were Tarsus Pharmaceuticals’s earnings last quarter?
      Tarsus Pharmaceuticals released its earnings results on Nov 09, 2023. The company reported -$1.28 earnings per share for the quarter, beating the consensus estimate of -$1.35 by $0.07.
        Is Tarsus Pharmaceuticals overvalued?
        According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Tarsus Pharmaceuticals pay dividends?
          Tarsus Pharmaceuticals does not currently pay dividends.
          What is Tarsus Pharmaceuticals’s EPS estimate?
          Tarsus Pharmaceuticals’s EPS estimate is -$1.37.
            How many shares outstanding does Tarsus Pharmaceuticals have?
            Tarsus Pharmaceuticals has 33,104,610 shares outstanding.
              What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
              Tarsus Pharmaceuticals reported an EPS of -$1.28 in its last earnings report, beating expectations of -$1.35. Following the earnings report the stock price went up 12.203%.
                Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
                Among the largest hedge funds holding Tarsus Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Tarsus Pharmaceuticals’s shares valued at 23M.


                  Company Description

                  Tarsus Pharmaceuticals

                  Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.


                  Top 5 ETFs holding TARS

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  Schwab U.S. Broad Market ETF
                  iShares Russell 3000 ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold TARS. The ETFs are listed according to market value of TARS within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Eagle Pharmaceuticals
                  Corbus Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis